Anakinra is a recombinant non-glycosylated form of human interleukin-1 receptor antagonist (IL-1 Ra) used with success in pediatric and adult patients with sJIA, AOSD and subsequently in patients with MAS (Sönmez et al., 2018; Monteagudo et al., 2020). This evidence concerns the gene IL1B and macrophage activation syndrome.